HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Subscribe to be notified of changes or updates to this page.
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”).
A gene in stem cells will then be edited to help the stem cells make more fetal hemoglobin. Higher levels of fetal hemoglobin can improve red blood cell sickling.
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").